18 completed, 3 recruiting, 1 active not recruiting. 13 Phase 2, 12 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 10, Recruiting 3 |
| Phase 1 | 12 | Completed 12 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow de Novo Myelodysplastic Syndrome: new trials by email Literature Review of de Novo Myelodysplastic Syndrome trials Research Report on de Novo Myelodysplastic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Cladribine, Cytarabine, Filgrastim - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | University of Washington | 84 | 2016-12-01 | 2023-07-05 |
| Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome Azacitidine, Ibrutinib - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 | Completed | Brian Jonas | 21 | 2016-05-17 | 2022-10-06 |
| Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Laboratory Biomarker Analysis, Selinexor - Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 | Completed | University of Chicago | 12 | 2015-09-04 | 2021-05-13 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia Cladribine, Cytarabine, Gilteritinib - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 508 | 2014-05-19 | 2026-05-20 |
| Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies Azacitidine, Decitabine, Laboratory Biomarker Analysis - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 | Completed | Mayo Clinic | 63 | 2014-05-01 | 2019-10-30 |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 54 | 2014-04-22 | 2024-01-24 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Cladribine, Cytarabine, Filgrastim - Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 199 | 2014-01-23 | 2020-01-10 |
| Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant Azacitidine (AZC), Decitabine, Quality-of-Life Assessment - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome | Phase 2 | Completed | Fred Hutchinson Cancer Center | 50 | 2013-08-19 | 2024-02-15 |
| Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome Anti-Thymocyte Globulin, Cyclosporine, Filgrastim - Aplastic Anemia, de Novo Myelodysplastic Syndrome | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 140 | 2012-06-25 | 2026-06-22 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine - Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 68 | 2010-07-15 | 2022-08-04 |
| Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Lenalidomide, Cytarabine, Idarubicin - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 61 | 2010-05-01 | 2014-12-23 |
| Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Bone Marrow Biopsy, Epoetin Alfa, Laboratory Biomarker Analysis - Anemia, Chronic Myelomonocytic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 247 | 2009-04-20 | 2026-10-01 |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2008-02-04 | 2025-04-02 |
| Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Cytarabine, Decitabine, Filgrastim-sndz - Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 270 | 2007-04-04 | 2026-10-07 |
| Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Cyclosporine - Acute Myeloid Leukemia in Remission, de Novo Myelodysplastic Syndrome | Phase 2 | Completed | Fred Hutchinson Cancer Center | 6 | 2007-02-01 | 2020-01-29 |
| Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Azacitidine, Entinostat, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 197 | 2006-08-01 | 2017-02-02 |
| Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases Belinostat, Azacitidine, Laboratory Biomarker Analysis - Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 56 | 2006-06-01 | 2014-12-23 |
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis - Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 77 | 2006-01-01 | 2020-01-31 |
| Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia filgrastim, busulfan, cyclosporine - Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 34 | 2005-11-01 | 2025-08-26 |
| Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia Sorafenib Tosylate - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2005-10-01 | 2015-04-28 |
Showing 20 of 22. Sign in to see all of them.
Leukemia, Myeloid, Acute (14) · Myelodysplastic Syndromes (12) · Leukemia, Myelomonocytic, Chronic (10) · Leukemia, Myelomonocytic, Acute (7) · Anemia, Refractory, with Excess of Blasts (4) · Blast Crisis (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Leukemia, Promyelocytic, Acute (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Anemia, Refractory (3) · Leukemia, Biphenotypic, Acute (3) · Leukemia, Erythroblastic, Acute (3) · Leukemia, Megakaryoblastic, Acute (3) · Leukemia, Monocytic, Acute (3) · Myeloproliferative Disorders (3)
Hematologic Diseases (22) · Hemic and Lymphatic Diseases (22) · Bone Marrow Diseases (20) · Neoplasms (20) · Neoplasms by Histologic Type (20) · Leukemia, Myeloid (19) · Leukemia (18) · Chronic Disease (13) · Disease Attributes (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Myelodysplastic-Myeloproliferative Diseases (9) · Anemia (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7)
Azacitidine (7) · fludarabine phosphate (6) · Cyclosporine (5) · Cytarabine (5) · Filgrastim (5) · Granulocyte Colony-Stimulating Factor (5) · Mycophenolic Acid (5) · Cyclosporins (4) · Whole-Body Irradiation (4) · Cladribine (3) · Decitabine (3) · Idarubicin (3) · Injections (3) · Peripheral Blood Stem Cell Transplantation (3) · Antilymphocyte Serum (2)
National Cancer Institute (NCI) (8) · Fred Hutchinson Cancer Center (5) · M.D. Anderson Cancer Center (4) · Brian Jonas (1) · Masonic Cancer Center, University of Minnesota (1) · Mayo Clinic (1) · University of Chicago (1) · University of Washington (1)
United States (22) · Brazil (1) · Canada (1) · Germany (1) · Italy (1) · New Zealand (1)
Brenda Sandmaier (2) · Tapan M Kadia (2) · Amit K Verma (1) · Anna Halpern (1) · Aref Al-Kali (1) · Bart L. Scott (1) · Brian Jonas (1) · Christen Ebens, MD (1) · Hans-Peter Kiem (1) · Hongtao Liu (1) · Jayastu Senapati (1) · Jorge Cortes (1) · Keith W Pratz (1) · Olatoyosi Odenike (1) · Ravi Vij (1)
PMID 26577691, PMID 32499241, PMID 19546476, PMID 19652201, PMID 20952518, PMID 29702001, PMID 30630975, PMID 31212080, PMID 32777116, PMID 33439748, PMID 34312462, PMID 34329576, PMID 37339483, PMID 40193193, PMID 40500616
P30CA015704 (5), P01CA018029 (2), P30CA006973 (2), P30CA014599 (2), U01CA062491 (2), U01CA070095 (2), U10CA021115 (2), U10CA180820 (2), P01CA049639 (1), P30CA015083 (1), P30CA016058 (1), P30CA016672 (1), U01CA062461 (1), U01CA069852 (1), U01CA069912 (1)